Applications

Palbociclib was approved for marketing in the United States in February 2015. As the world's first approved CDK4/6 inhibitor, palbociclib has become the first-line therapy for HR+/HER2- breast cancer patients, and has been approved by more than 90 worldwide. Approved by the state for first-line and second-line treatment of HR+/HER2- breast cancer, it occupies most of the CDK4/6 inhibitor market.

Palbociclib in combination with endocrine disorders (such as letrozole, fulvestrant, etc.) has a very, very good effect on ER/PR-positive, HER2-negative breast cancer.

Technical specification

FORM A

Packaging

Packaging is confirmed with the quotation.

On a small screen, scroll the technical table horizontally.

Published reference specifications. Confirm the current grade, SDS / TDS / COA, packaging and delivery terms with your quotation.